People with MS who engage in more physical activity tend to have less severe physical and cognitive disability, a study demonstrated.

Background Physical activity has been associated with neuroprotective and immunomodulatory benefits, potentially influencing ...

Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational ...

The investigational therapy fenebrutinib was as effective as Ocrevus for reducing disability progression in people with PPMS, a trial showed.

Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...

Please provide your email address to receive an email when new articles are posted on . A study examined the effects of exercise in 3,000 patients with MS for up to 15 years. More physical activity ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton’s tyrosine kinase (BTK ...

In a significant advance for multiple sclerosis (MS) research, a new study has uncovered a potential link between certain initial symptoms and long-term disability outcomes. The research, published in ...

Please provide your email address to receive an email when new articles are posted on . Tolebrutinib was associated with a 31% reduced risk for 6-month confirmed disability progression vs. placebo.

—A large international team of experts examined relapse activity and disability progression among pregnant and nonpregnant women of reproductive age with moderate-to-severe multiple sclerosis (MS).

Fenebrutinib numerically reduced the risk of disability progression by 12% compared to OCREVUS as early as 24 weeks; additional analysis showed potential benefit in upper limb function Fenebrutinib ...